Eye on the B-ALL: B-cell receptor repertoires reveal persistence of numerous B-lymphoblastic leukemia subclones from diagnosis to relapse

Leukemia

Volumn 30, Issue 12, 2016, Pages 2312-2321

  Bashford Rogers, R J M ^a,b   Nicolaou, K A ^c   Bartram, J ^d,e   Goulden, N J ^d   Loizou, L ^f   Koumas, L ^c   Chi, J ^c   Hubank, M ^e   Kellam, P ^a,g   Costeas, P A ^c   Vassiliou, G S ^a,c,h  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Center for Study of Hematological Malignancies   (Cyprus)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Pediatric Oncology Hematology Clinic   (Cyprus)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h Cambridge Biomedical Research Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CELL CLONE; CLONAL VARIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PHYLOGENY; PRIORITY JOURNAL; CELL SURVIVAL; DNA SEQUENCE; GENETICS; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; SOMATIC HYPERMUTATION;

CELL SURVIVAL; CLONE CELLS; HUMANS; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RECEPTORS, ANTIGEN, B-CELL; RECURRENCE; SEQUENCE ANALYSIS, DNA; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 84975137934     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.142     Document Type: Article

References (55)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
2. Fielding AK. The treatment of adults with acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2008, 381-389, doi:10.1182/asheducation- 2008.1.381.
3. Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol 2006; 24: 541-570.
4. Maizels N. Somatic hypermutation: how many mechanisms diversify V region sequences? Cell 1995; 83: 9-12.
5. Kelsoe G. In situ studies of the germinal center reaction. Adv Immunol 1995; 60: 267-288.
6. Neuberger MS, Milstein C. Somatic hypermutation. Curr Opin Immunol 1995; 7: 248-254.
7. Bruggemann M, Schrauder A, Raff T, Pfeifer H, Dworzak M, Ottmann OG et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-535.
8. Bashford-Rogers RJ, Palser AL, Huntly BJ, Rance R, Vassiliou GS, Follows GA et al. Network properties derived from deep sequencing of human B-cell receptor repertoires delineate B-cell populations. Genome Res 2013; 23: 1874-1884.
9. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2013; 28: 1299-1307.
10. Bashford-Rogers R, Palser A, Idris S, Carter L, Epstein M, Callard R et al. Capturing needles in haystacks: comparison of B-cell receptor sequencing methods. BMC Immunol 2014; 15: 29.
11. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008; 111: 5477-5485.
12. van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 1998; 352: 1731-1738.
13. Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP et al. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. Lancet Oncol 2015; 16: 465-474.
14. Paietta E. Assessing minimal residual disease (MRD) in leukemia: a changing definition and concept? Bone Marrow Transplant 2002; 29: 459-465.
15. Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL et al. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. Leukemia 2003; 17: 1566-1572.
16. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13: 1901-1928.
17. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol 2013; 30: 772-780.
18. Wilgenbusch JC, Swofford D. Inferring evolutionary trees with PAUP. Curr Protoc Bioinformatics 2003; Chapter 6: Unit 6.4.
19. Posada D. Using MODELTEST and PAUP∗ to select a model of nucleotide substitution. Curr Protoc Bioinformatics 2003; Chapter 6: Unit 6.5.
20. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990; 215: 403-410.
21. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17: 2318-2357.
22. Bain BJ. Bone marrow aspiration. J Clin Pathol 2001; 54: 657-663.
23. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer- Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604-611.
24. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
25. Greiff V, Menzel U, Haessler U, Cook SC, Friedensohn S, Khan TA et al. Quantitative assessment of the robustness of next-generation sequencing of antibody variable gene repertoires from immunized mice. BMC Immunol 2014; 15: 40.
26. Morris H, DeWolf S, Robins H, Sprangers B, LoCascio SA, Shonts BA et al. Tracking donor-reactive T cells: Evidence for clonal deletion in tolerant kidney transplant patients. Sci Transl Med 2015; 7: 272ra210.
27. Bashford-Rogers RJ, Palser AL, Idris SF, Carter L, Epstein M, Callard RE et al. Capturing needles in haystacks: a comparison of B-cell receptor sequencing methods. BMC Immunol 2014; 15: 29.
28. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009; 1: 12ra23.
29. Hoffmann R, Seidl T, Neeb M, Rolink A, Melchers F. Changes in gene expression profiles in developing B cells of murine bone marrow. Genome Res 2002; 12: 98-111.
30. Korsmeyer SJ, Arnold A, Bakhshi A, Ravetch JV, Siebenlist U, Hieter PA et al. Immunoglobulin gene rearrangement and cell surface antigen expression in acute lymphocytic leukemias of T cell and B cell precursor origins. J Clin Invest 1983; 71: 301-313.
31. Strauchen JA, Mandeli JP. Immunoglobulin expression in B-cell lymphoma. Immunohistochemical study of 345 cases. Am J Clin Pathol 1991; 95: 692-695.
32. Dupuis A, Gaub MP, Legrain M, Drenou B, Mauvieux L, Lutz P et al. Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations. Leukemia 2013; 27: 503-507.
33. Beishuizen A, Hahlen K, Hagemeijer A, Verhoeven MA, Hooijkaas H, Adriaansen HJ et al. Multiple rearranged immunoglobulin genes in childhood acute lymphoblastic leukemia of precursor B-cell origin. Leukemia 1991; 5: 657-667.
34. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. Nat Genet 2014; 46: 116-125.
35. Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al. The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013; 45: 242-252.
36. Boyd SD, Marshall EL, Merker JD, Maniar JM, Zhang LN, Sahaf B et al. Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing. Sci Transl Med 2009; 1: 12ra23.
37. Langerak AW, Dongen JJM. Multiple clonal Ig/TCR products: implications for interpretation of clonality findings. J Hematopathol 2011; 5: 35-43.
38. Szczepanski T, Willemse MJ, Brinkhof B, van Wering ER, van der Burg M, van Dongen JJ. Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood 2002; 99: 2315-2323.
39. Feldhahn N, Henke N, Melchior K, Duy C, Soh BN, Klein F et al. Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1-transformed acute lymphoblastic leukemia cells. J Exp Med 2007; 204: 1157-1166.
40. Messina M, Chiaretti S, Iacobucci I, Tavolaro S, Lonetti A, Santangelo S et al. AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile. Br J Haematol 2011; 152: 727-732.
41. Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D, Soverini S et al. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. Leukemia 2010; 24: 66-73.
42. Hardianti MS, Tatsumi E, Syampurnawati M, Furuta K, Suzuki A, Saigo K et al. Presence of somatic hypermutation and activation-induced cytidine deaminase in acute lymphoblastic leukemia L2 with t(14;18)(q32;q21). Eur J Haematol 2005; 74: 11-19.
43. Jiao W, Vembu S, Deshwar AG, Stein L, Morris Q. Inferring clonal evolution of tumors from single nucleotide somatic mutations. BMC Bioinformatics 2014; 15: 35.
44. Zheng NY, Wilson K, Jared M, Wilson PC. Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation. J Exp Med 2005; 201: 1467-1478.
45. Saini J, Hershberg U. B cell variable genes have evolved their codon usage to focus the targeted patterns of somatic mutation on the complementarity determining regions. Mol Immunol 2015; 65: 157-167.
46. Yaari G, Kleinstein SH. Practical guidelines for B-cell receptor repertoire sequencing analysis. Genome Med 2015; 7: 121.
47. Martins EP, Housworth EA. Phylogeny shape and the phylogenetic comparative method. Syst Biol 2002; 51: 873-880.
48. Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 2011; 471: 235-239.
49. Tzoneva G, Perez-Garcia A, Carpenter Z, Khiabanian H, Tosello V, Allegretta M et al. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL. Nat Med 2013; 19: 368-371.
50. Meyer JA, Wang JH, Hogan LE, Yang JJ, Dandekar S, Patel JP et al. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013; 45: 290-294.
51. Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K et al. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. Nat Commun 2014; 5: 3469.
52. Ma X, Edmonson M, Yergeau D, Muzny DM, Hampton OA, Rusch M et al. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia. Nat Commun 2015; 6: 6604.
53. Mullighan CG. Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest 2012; 122: 3407-3415.
54. Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood 2015; 125: 2486-2496.
55. Richards S, Burrett J, Hann I, Chessells J, Hill F, Bailey C. Improved survival with early intensification: combined results from the Medical Research Council childhood ALL randomised trials, UKALL X and UKALL XI. Medical Research Council Working Party on Childhood Leukaemia. Leukemia 1998; 12: 1031-1036.